Geron Corporation to Present Data Highlighting Clinical and Biological Activity of RYTELO® (imetelstat) at ASH 2026

Geron (Nasdaq: GERN) will present six posters at the American Society of Hematology Annual Meeting on December 12–16, 2026.

Rhea-AI Summary

Geron (Nasdaq: GERN) will present six posters at the American Society of Hematology Annual Meeting on December 12–16, 2026. The meeting takes place in New Orleans, with Geron's poster sessions scheduled for December 12 and 13.

The presentations include an analysis of blood-cell response patterns supporting the approved dosing of RYTELO (imetelstat) in lower-risk myelodysplastic syndromes and updated IMproveMF trial results for imetelstat plus ruxolitinib in myelofibrosis. Other posters address telomerase inhibition in chronic myelomonocytic leukemia, biological mechanisms in acute myeloid leukemia and KAT6A-rearranged leukemia, and the Phase 1/1b IMAGINE combination trial in relapsed acute myeloid leukemia. No numerical clinical results are provided; the post-hoc analyses carry qualifications and limitations detailed in the full presentations.

Argus Nov 4 session 22 alerts

+16.13% close to close 1.8x rel. volume Open Argus

Details

Market move: GERN +16.13% in the Nov 4 session. ASH 2026 data presentations

+11.3% Peak in 8 hr 38 min

$693.87M Mkt Cap at Peak Alert

On Nov 4, the day this news came out, GERN closed 16.13% above the previous close. Argus tracked a peak move of +11.3% during that session. Our momentum scanner recorded 22 alerts for this stock that day. That session’s volume was 1.8x the stock’s average daily volume.

Data tracked by StockTitan Argus for the Nov 4 session.

Key Figures

Accepted abstracts: 6 abstracts

Accepted abstracts

6 abstracts

Accepted for poster presentation at ASH 2026

Key Terms

pharmacokinetic/pharmacodynamic, cytopenias, myelodysplastic syndromes, telomerase inhibition

4 terms

pharmacokinetic/pharmacodynamic technical

"a population pharmacokinetic/pharmacodynamic approach"

Pharmacokinetic/pharmacodynamic (PK/PD) describes two linked ideas: pharmacokinetics is how a drug moves through the body (how fast it’s absorbed, spread, broken down and eliminated) and pharmacodynamics is how the drug affects the body (the relationship between dose and response). Investors care because strong, predictable PK/PD data reduce uncertainty about effective dosing, safety and likelihood of regulatory approval—similar to knowing a car’s fuel efficiency and braking before buying, which lowers the risk of a costly surprise.

cytopenias medical

"the relationship between dosing, hematologic response and cytopenias"

Cytopenias are reductions in one or more types of blood cells — red cells, white cells or platelets — that can lead to anemia, infection risk or bleeding problems. For investors, cytopenias matter because they are common safety signals in clinical trials and marketed therapies; persistent or severe cytopenias can force dose changes, regulatory restrictions, or product withdrawals, affecting a drug’s commercial prospects and a company’s valuation.

myelodysplastic syndromes medical

"in lower-risk myelodysplastic syndromes (LR-MDS)"

Myelodysplastic syndromes are a group of disorders in which the bone marrow — the body’s blood cell factory — makes blood cells that are abnormal or too few, leading to anemia, infections, or bleeding and sometimes progressing to leukemia. Investors monitor them because demand for effective drugs, clinical trial results, and regulatory approvals can materially affect the revenues and valuations of healthcare companies and influence projected treatment costs and market opportunities.

telomerase inhibition medical

"the science of telomerase inhibition"

Blocking or reducing the activity of telomerase, the enzyme that adds DNA repeats (telomeres) to the ends of chromosomes; without telomerase activity, telomeres shorten each time a cell divides, which can eventually trigger cellular senescence or programmed cell death. Telomerase inhibition is a therapeutic strategy most often discussed in oncology because many cancer cells rely on telomerase to maintain unlimited division; its effects depend on how rapidly a cell divides and on the cell's existing telomere length, so clinical impact is typically delayed and primarily affects dividing cells.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

New analyses further characterize the clinical activity and approved dosing regimen of RYTELO® (imetelstat) in lower-risk MDS

FOSTER CITY, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a hematology-focused commercial stage biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, today announced that six abstracts have been accepted for poster presentation at the 68^th American Society of Hematology (ASH) Annual Meeting, to be held December 12-16, 2026, in New Orleans, LA. The presentations include new analyses providing further insight into the clinical activity and approved dosing regimen of RYTLEO® (imetelstat) in lower-risk myelodysplastic syndromes (LR-MDS).

“As we continue to build on the evidence supporting RYTELO in lower-risk MDS, understanding the relationship between dosing, hematologic response and cytopenias is important to informing its appropriate use in clinical practice,” said Joseph E. Eid, M.D., Executive Vice President, Research and Development and Chief Medical Officer of Geron. “The data to be presented at ASH further supports the scientific rationale for our approved dosing regimen, while the broader research continues to deepen our understanding of imetelstat’s clinical and biological activity across hematologic malignancies. Together, these efforts reflect our commitment to deepening our understanding of the science of telomerase inhibition.”

ASH 2026 Poster Presentations

Presentation Title	Presenting Author	Abstract Number	Presentation Details
Imetelstat plus ruxolitinib in patients with intermediate-1/2 or high-risk myelofibrosis: updated results from the IMproveMF trial	John Mascarenhas, M.D.	#2013	Dec. 12, 2026; 5:30pm – 7:30pm ET
Analysis of hematologic response dynamics to support imetelstat-approved dosing in lower-risk myelodysplastic syndromes: a population pharmacokinetic/pharmacodynamic approach	Ashley Lennox, Ph.D.	#2069	Dec. 12, 2026; 5:30pm – 7:30pm ET
Telomere Maintenance as a Therapeutic Vulnerability in Chronic Myelomonocytic Leukemia: Rationale for Targeted Telomerase Inhibition with Imetelstat	Daniel Wiseman, Ph.D.	#2058	Dec. 12, 2026; 5:30pm – 7:30pm ET
Imetelstat couples lysosome-dependent lipid remodelling to a targetable sterol-regulatory vulnerability in acute myeloid leukaemia	Claudia Bruedigam, Ph.D.	#3244	Dec. 13, 2026; 6:00pm – 8:00pm ET
Mechanisms leading to self-renewal capacity of KAT6A-rearranged leukemia	Florian Heidel, M.D.	#1698	Dec. 13, 2026; 6:00pm – 8:00pm ET
Phase 1/1b trial of imetelstat and azacitidine with or without venetoclax in relapsed acute myeloid leukemia (IMAGINE trial)	Douglas Tremblay, M.D.	#3402	Dec. 13, 2026; 6:00pm – 8:00pm ET

Please see the full presentations for important qualifications and limitations on these post-hoc analyses.

About RYTELO (imetelstat)
RYTELO (imetelstat) is an oligonucleotide telomerase inhibitor approved in the U.S. for the treatment of adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). It is indicated to be administered as an intravenous infusion over two hours every four weeks.

In addition, RYTELO is approved in the European Union as a monotherapy for the treatment of adult patients with transfusion-dependent anemia due to very low, low or intermediate risk myelodysplastic syndromes without an isolated deletion 5q cytogenetic (non-del 5q) abnormality and who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy.

RYTELO is a first-in-class treatment that works by inhibiting telomerase enzymatic activity. Telomeres are protective caps at the end of chromosomes that naturally shorten each time a cell divides. In LR-MDS, abnormal bone marrow cells often express the enzyme telomerase, which rebuilds those telomeres, allowing for uncontrolled cell division. Developed and exclusively owned by Geron, RYTELO is the first and only telomerase inhibitor approved by the U.S. Food and Drug Administration and the European Commission.

Please see RYTELO (imetelstat) full Prescribing Information, including Medication Guide, available at https://pi.geron.com/products/US/pi/rytelo_pi.pdf.

About Geron
Geron is a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer. Because patients cannot wait, we approach our work with urgency, bringing together deep expertise in telomerase biology with patient perspectives and insights from clinical research and real-world care. Our medicine, RYTELO® (imetelstat), is approved in the United States and European Union for certain patients with lower-risk myelodysplastic syndromes (LR-MDS). Geron is a commercial-stage company with offices in Parsippany, New Jersey and Foster City, California. To learn more, visit www.geron.com or follow us on LinkedIn.

Investors and Media
Dawn Schottlandt
Senior Vice President, Investor Relations and Corporate Affairs
dschottlandt@geron.com